Allogeneic and Autologous Cell Therapies Report 2022
In December 2021, Informa Connect and Catalent conducted a worldwide survey of cell therapy professionals to understand the emerging trends in both the allogeneic and autologous cell therapy space. Respondents were asked about their focus areas, product types and phases of their programs, in addition to their decision-making and the most significant challenges to their manufacturing goals.
The full report reveals cell therapy manufacturing trends amid the rapid progression of cell therapy technologies.
Key findings include:
- 63% of cell therapy professionals are working on both autologous and allogeneic products
- Supply chain bottlenecks are the most common hurdle that cell therapy professionals have experienced with their programs
- Respondents gave valuable insights into next-generation innovative technologies they are most likely to adopt
Read or download the report here or by clicking on the image below.